Akademik Veri Yönetim Sistemi
ACTA ONCOLOGICA TURCICA, cilt.55, sa.2, ss.103-108, 2022 (Hakemli Dergi)
Introduction: The aim of the study was to evaluate the relationship between CD23 expression status and clinical features in multiple myeloma patients. Materials and methods: We retrospectively analyzed the data of 196 patients diagnosed with multiple myeloma in our institution between May 2010 and August 2018. Results: Compared to the CD23 negative group, in the CD23 positive group, the incidence of anemia was significantly lower, and the incidence of CD20 expression and the rate of R-ISS stage 1 patients was significantly higher. No similar association was found between R-ISS and other cell surface markers Discussion: In conclusion, clinical presentations of multiple myeloma patients with aberrant CD23 expression show some clinical differences from those without. The fact that MM patients with CD23 expression were clustered in the favorable prognostic group according to R-ISS drew attention to its prognostic value. For MM patients, the addition of CD23 to the routine flow cytometry panel may be considered. In this respect, examination of CD23 expression is required in a larger group of cases to assess its prognostic value in MM.